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ABSTRACT
ThoughmedicinesthattargetmRNAareunderactive
investigation, there has been little or no effort to
develop mRNA itself as a medicine. Here, we report
thesynthesisofa130-ntmRNAsequenceencoding a
33-amino-acid peptide that includes the sequence of
glucagon-like peptide-1, a peptide that stimulates
glucose-dependent insulin secretion from the
pancreas. The synthesis method used, which had
previously been developed in our laboratory, was
based on the use of 2-cyanoethoxymethyl as the
20-hydroxy protecting group. We also developed
novel, highly reactive phosphotriester
pyrophosphorylating reagents to pyrophosphorylate
the 50-end of the 130-mer RNA in preparation for
capping. We completed the synthesis of the artificial
mRNA by the enzymatic addition of a 50-cap and a
30-poly(A) tail to the pyrophosphorylated 130-mer
and showed that the resulting mRNA supported
protein synthesis in a cell-free system and in whole
cells. As far as we know, this is the first time that
mRNA has been prepared from a chemically
synthesized RNA sequence. As well as providing a
research tool for the intracellular expression of
peptides, the technology described here may be
used for the production of mRNA for medical
applications.
Introduction
RNA vaccines against inﬂuenza viruses, unknown viruses
or cancer are leading to new medical applications (1–3).
Although peptide vaccines induce humoral immunity
through major histocompatibility complex (MHC) class
II proteins, mRNA-based vaccines can induce the
cell-mediated immunity that is important for cancer
vaccines through MHC class I proteins. This is because
mRNA can direct the synthesis of antigenic proteins
directly in the cell, whereas peptide vaccines must intro-
duce antigenic proteins into the cell from the outside (4).
There is also the possibility of developing mRNA itself as
a new class of therapeutic agent without toxicity. For
medical applications, it is essential to have a technology
for producing mRNA as a single molecular species in
highly pure form by a method that can be scaled up as
necessary. As well as being a useful tool for the intracel-
lular expression of oligopeptides, such a technology may
also be used in basic and applied research on non-coding
RNA.
mRNA is usually prepared by enzymatic synthesis with
RNA polymerase from a DNA template followed by en-
zymatic addition of the 50-cap and the 30-poly(A) tail (5).
However, mRNA prepared in this way may contain tran-
scription errors (6), can only be produced on a laboratory
scale, and is not pure enough for use in the development of
medicines. Furthermore, enzymatic synthesis cannot be
used to incorporate modiﬁed nucleotides into desired pos-
itions in the mRNA sequence, which may be important to
improve nuclease resistance without affecting function or
to enhance other properties of the mRNA such as
membrane penetration (7). The drawbacks of enzymatic
synthesis can be overcome by chemically synthesizing the
mRNA sequence before adding the 50-cap and the
30-poly(A) tail. Chemical synthesis of the RNA sequence
also allows the artiﬁcial mRNAs to be freely designed. An
example of a synthetic capped 42-mer mRNA has been
reported (8), but it was synthesized in three fragments
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30-poly(A) tail.
With these considerations in mind, we designed an
artiﬁcial mRNA for chemical synthesis in a single synthe-
sizer run followed by enzymatic addition of a 50-cap
and a 30-poly(A) tail. Before the addition of the cap, the
50-end of the RNA must be pyrophosphorylated. We
devised a scheme in which the artiﬁcial mRNA is
prepared by the following steps: (i) chemical synthesis of
the mRNA sequence in the solid phase, (ii)
pyrophosphorylation of the synthetic RNA at the 50-end
on the solid support, (iii) cleavage of the
50-pyrophosphorylated RNA from the solid support
followed by enzymatic capping and (iv) enzymatic
polyadenylation of the 50-capped RNA at the 30-end. At
the outset of this study, it was not known whether an
RNA oligomer of the necessary length could be chemically
synthesized or whether the 50-end of such a long RNA
oligomer could be pyrophosphorylated.
We have previously developed a method for
synthesizing very long RNA oligomers with
2-cyanoethoxymethyl (CEM) as the 20-hydroxy protecting
group (9). By the CEM method, RNA can be synthesized
more simply and easily than by the conventional TBDMS
method described by Usman et al. (10). We have used the
CEM method to synthesize a 110-nt RNA oligomer with
the sequence of a candidate precursor microRNA and
shown that it had biological activity (11). To our know-
ledge, this 110-mer is the longest RNA reported to have
been chemically synthesized to date. In the present study,
we used the CEM method to synthesize the 130- and
170-mer sequences required for our designed artiﬁcial
mRNAs.
After the mRNA sequence has been synthesized, it is
ﬁrst monophosphorylated and then pyrophosphorylated
at the 50-end. Monophosphorylation of RNA proceeds
almost quantitatively with commercially available
phosphorylating reagents (12). However, existing
phosphorylating reagents for the pyrophosphorylation
of RNA are not very reactive (12,13). Because reagents
have only poor accessibility to the internal pores of a
solid support ﬁlled with long RNA oligomers, the low
reactivity of existing pyrophosphorylating reagents
presents a real problem for pyrophosphorylation of the
50-end of very long RNA oligomers on the solid support.
Therefore a more reactive pyrophosphorylating reagent is
necessary.
Here, we report the synthesis by the CEM method
of a 130-nt mRNA sequence encoding a 33-amino-acid
peptide that includes the sequence of glucagon-like
peptide-1 (GLP-1), a peptide that stimulates
glucose-dependent insulin secretion from the pancreas
(14–16). We also developed novel, highly reactive
pyrophosphorylating reagents and used them to
pyrophosphorylate the 130-mer RNA at the 50-end. We
completed the synthesis of the artiﬁcial mRNA by
enzymatically adding a 50-cap and a 30-poly(A) tail. We
showed that our artiﬁcial mRNA supported GLP-1 pro-
duction in a cell-free protein synthesis system and in
Chinese hamster ovary (CHO) cells.
MATERIALS AND METHODS
General methods
UV spectra were recorded with a Hitachi U-2810
double-beam spectrophotometer.
31P-NMR spectra were
recorded on a Bruker DRX 500 spectrometer with
3-trimethylsilylpropionate-2,2,3,3-d
4 sodium salt or
H3PO4 as the standard. Electrospray ionization (ESI)
mass spectra were recorded on a JEOL JMS-SX 102
mass spectrometer. Analytical high performance liquid
chromatography (HPLC) was performed on a Shimadzu
HPLC system equipped with a DNAPac PA100
(4 250mm, Dionex) or Mightysil RP-18 GP
(4.6 150mm, Kanto Kagaku) column. Matrix-assisted
laser desorption/ionization time-of-ﬂight (MALDI–TOF)
mass spectra were obtained with a Bruker Autoﬂex
(Bruker Daltonics, Billerica, MA) or a Voyager-DE STR
(Applied Biosystems, Foster City, CA, USA) spectrom-
eter. Reagents and solvents were purchased from commer-
cial suppliers and used without further puriﬁcation.
Anhydrous solvents were from Wako Pure Chemical
Industries (Osaka, Japan) and tetrabutylammonium
ﬂuoride (TBAF) was from Nacalai Tesque (Kyoto,
Japan). The following HPLC solvent systems were used:
for reverse-phase HPLC, buffer A [5% acetonitrile in
50mM triethylammonium acetate (TEAA), pH 7] and
buffer B (90% acetonitrile in 50mM TEAA, pH 7); and
for anion-exchange HPLC, buffer C (10% acetonitrile in
25mM Tris–HCl, pH8.0) and buffer D (10% acetonitrile
containing 700mM NaClO4 in 25mM Tris–HCl, pH 8.0).
Dialysis was carried out with a 1000-Da molecular-weight-
cutoff Spectra/Pore membrane (Spectrum Laboratories,
Laguna Hills, CA, USA).
Synthesis of 130-mer RNA
Commercially available controlled-pore glass (CPG) solid
support with a pore size of 2000A ˚ derivatized with N
6-
benzoyl-50-O-(4,40-dimethoxytrityl)-20-O-(t-butyldimethyl-
silyl) adenosine was placed in a column ﬁtted with a ﬁlter
and the column was installed in an Applied Biosystems
Expedite Model 8909 nucleic acid synthesizer. The RNA
was synthesized on a 0.6-mmol scale from the
CEM amidites (CEM-A phosphoramidite, N
6-acetyl-50-
O-(4,40-dimethoxytrityl)-20-O-(2-CEM) adenosine 30-O-
(2-cyanoethyl)-N,N-diisopropylphosphoramidite; CEM-C
phosphoramidite, N
4-acetyl-50-O-(4,40-dimethoxytrityl)-20-
O-(2-CEM) cytidine 30-O-(2-cyanoethyl)-N,N-diisopropyl-
phosphoramidite; CEM-G phosphoramidite, N
2-
phenoxyacetyl-50-O-(4,40-dimethoxytrityl)-20-O-(2-CEM)
guanosine 30-O-(2-cyanoethyl)-N,N-diisopropylphospho
ramidite; CEM-U phosphoramidite, 50-O-(4,40-dimetho-
xytrityl)-20-O-(2-CEM) uridine 30-O-(2-cyanoethyl)-N,N-
diisopropylphosphoramidite) were prepared as described
earlier (11). The detritylation reagent was 3% trichloro-
acetic acid in dichloromethane (CH2Cl2). For the coupling
reaction, amidites were used as 0.05M solutions in
acetonitrile (CH3CN), and the activator was
5-benzylmercaptotetrazole (BMT). The capping reagent
was a mixture of phenoxyacetic anhydride (Pac2O) in
tetrahydrofuran (THF) and N-methylimidazole (NMI)
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0.1M iodine (I2) in THF/pyridine/water.
Monophosphorylation of 130-mer RNA at the 50-end
Monophosphorylation of the 130-mer RNA was carried
out with the 130-mer RNA still attached to the solid
support. The solid support with the attached 130-mer
RNA (65.3mg, 0.5mmol loading) was placed in a Libra
tube (HiPep Laboratories, Kyoto, Japan), washed three
times with dry CH3CN (3 3ml) under mild argon
pressure from an argon-ﬁlled balloon attached to the
Libra tube, and dried in vacuo for 1h. To the Libra tube
BMT (30.8mg, 160mmol) and 0.1M (2-cyanoethoxy)-2-
[20-O-(4,40-dimethoxytrityloxy)ethylsulfonyl]ethoxy-N,N-
diisopropylaminophosphine in CH3CN (400ml, 40mmol)
were added and the mixture was left to stand for 10min.
The liquid was removed under mild argon pressure, BMT
(30.8mg, 160mmol) and 0.1M (2-cyanoethoxy)-2-[20-O-
(4,40-dimethoxytrityloxy)ethylsulfonyl]ethoxy-N,N-diisopr
opylaminophosphine in CH3CN (400ml, 40mmol) were
added again, and the mixture was again left for 10min.
For subsequent treatment, the following protocol was
used: (i) washing with dry pyridine (3 1ml), (ii) oxida-
tion with 0.05M I2 solution in pyridine/water (9:1, v/v;
3 1ml for 15s), (iii) washing with dry pyridine
(3 1ml), (iv) washing with dry CH2Cl2 (3 1ml), (v)
capping with 0.2M Pac2Oi nC H 3CN (0.5ml) and 20%
NMI and 30% 2,6-lutidine in CH3CN (0.5ml) for 2min,
(vi) washing with dry CH2Cl2 (3 1ml), (vii) treatment
with 3% dichloroacetic acid in toluene (3 2ml; 15s),
(viii) washing with dry CH2Cl2 (3 1ml), (ix) treatment
with N,O-bis(trimethylsilyl)acetamide (BSA)-pyridine
(1:1, v/v; 360ml) for 20min, (x) addition of
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (72ml) for
10min, (xi) washing with dry pyridine (3 1ml), (xii)
washing with dry CH2Cl2 (3 1ml), (xiii) treatment with
MeOH/triethylamine (Et3N) (9:1, v/v; 2ml) for 3h, (xiv)
washing with dry CH3CN (3 2ml) and (xv) drying
in vacuo for 1h.
A portion (0.1 of 0.5mmol loading) of the solid support
with the attached 130-mer RNA monophosphorylated at
the 50-end was treated with 28% aqueous ammonia
solution and EtOH (3:1, v/v; 2ml) for 15h at 35 Ct o
cleave the phosphorylated RNA from the resin and to
remove the base-protecting groups. The reaction mixture
was ﬁltered and the ﬁltrate was concentrated to dryness
under reduced pressure. The residue was dissolved in dry
dimethyl sulfoxide (DMSO; 0.5ml), then CH3NO2 as an
acrylonitrile scavenger (10ml) and 1.0M TBAF in DMSO
(1.0ml) were added to remove the CEM group. The
reaction mixture was stirred for 5h at room temperature,
the reaction was quenched at 0 C with 1.0M Tris–HCl
(1.0ml), and the RNA oligomer was precipitated with
EtOH (40ml).
A small amount of the precipitate was treated
with MazF to generate fragments from the 50-end for
analysis by MALDI–TOF mass spectrometry.
Monophosphorylation of 130-mer RNA at the 50-end
was conﬁrmed to be quantitative. MALDI–TOF–MS
calcd for the 11-mer RNA fragment monophosphorylated
at the 50-end [M+H]
+, 3653.46; found, 3654.68. MALDI–
TOF–MS calcd for the 25-mer RNA fragment
monophosphorylated at the 50-end [M+H]
+, 8269.12;
found, 8271.38.
Pyrophosphorylation of 130-mer RNA at the 50-end
Pyrophosphorylation of the 130-mer RNA was carried
out with the 50-monophosphorylated 130-mer RNA still
attached to the solid support. Pyrophosphorylating
reagent was prepared by drying 1-hydroxy-6-(triﬂuoro-
methyl)benzotriazole (CF3-HOBt; 65.0mg, 320mmol)
in vacuo for 40min and adding 0.1M (2-cyanoethoxy)-2-
[20-O-(4,40-dimethoxytrityloxy)ethylsulfonyl]ethoxy-N,N-
diisopropylaminophosphine in CH3CN (640ml, 64mmol).
The mixture was stirred at room temperature for 2h.
While the pyrophosphorylating reagent was being
prepared, the solid support was washed with CH3CN
and dried in vacuo for 15min. Then half of the freshly
prepared pyrophosphorylating reagent was added to the
solid support with the attached 50-monophosphorylated
130-mer RNA (25.8mg, 0.2mmol) in a Libra tube. NMP
(36ml) was then added to the solid support and the
mixture was left for 30min. The liquid was removed
under mild argon pressure and the remaining half of the
pyrophosphorylating mixture was added to the solid
support. A further portion of NMP (36ml) was added
and the mixture was left for 30min. For subsequent treat-
ment, the following protocol was used: (i) washing with
dry pyridine (3 1ml), (ii) washing with dry CH2Cl2
(3 1ml), (iii) treatment with 3% dichloroacetic acid in
toluene (3 2ml; 15s), (iv) washing with dry CH2Cl2
(3 1ml), (v) treatment with BSA-pyridine (1:1, v/v;
360ml) for 20min, (vi) addition of DBU (72ml) and
leaving for 10min, (vii) washing with dry pyridine
(3 1ml), (viii) washing with dry CH2Cl2 (3 1ml) and
(ix) drying in vacuo for 15min.
The solid support (0.2mmol equiv.) with the attached
130-mer RNA pyrophosphorylated at the 50-end was
treated with 28% aqueous ammonia solution and EtOH
(3:1, v/v; 2ml) for 15h at 35 C. The reaction mixture was
ﬁltered and concentrated to dryness under reduced
pressure. The residue was dissolved in dry DMSO
(0.5ml), then CH3NO2 (10ml) and 1.0M TBAF in
DMSO (1.0ml) were added. The reaction mixture was
stirred for 5h at room temperature, the reaction was
quenched at 0 C with 1.0M Tris–HCl (1.0ml), and the
RNA oligomer was precipitated with EtOH (40ml).
The precipitate was puriﬁed by semipreparative
anion-exchange HPLC (DNAPac PA100, 9 250mm,
Dionex). Elution was carried out with a 5–45% linear
gradient of buffer D in buffer C. Dialysis was
carried out with a 1000-Da molecular-weight-cutoff
Spectra/Pore membrane. The solution was concentrated
to dryness under reduced pressure and the residue
was dissolved in water (1.0ml) to give 130-mer
RNA pyrophosphorylated at the 50-end (21.2 ODU;
15.9nmol, 8.0%).
A sample of the 50-pyrophosphorylated 130-mer was
treated with MazF to generate fragments from the
50-end for analysis by MALDI–TOF mass spectrometry.
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conﬁrmed to have proceeded. MALDI–TOF–MS calcd
for the 11-mer RNA fragment pyrophosphorylated at
the 50-end [M+H]
+, 3733.42; found, 3734.76. MALDI–
TOF–MS calcd for the fragment with 25-mer RNA
pyrophosphorylated at the 50-end [M+H]
+, 8349.08;
found, 8352.06.
Synthesis, monophosphorylation and pyrophosphorylation
of 170-mer RNA
A 170-mer RNA that includes a 40-mer poly(A) tail as a
part of the synthetic sequence was twice synthesized on a
0.6-mmol scale to give 1.2mmol of 170-mer. Of this,
1.1mmol was monophosphorylated at the 50-end and
1.0mmol of the monophosphorylated product was
pyrophosphorylated. All procedures used were similar to
those described above for 130-mer RNA. The ﬁnal yield
of 50-pyrophosphorylated product was 85.7 ODU
(47.8nmol, 4.8%).
A sample of the 50-pyrophosphorylated 170-mer was
treated with MazF to generate fragments from the
50-end for analysis by MALDI–TOF mass spectrometry.
Pyrophosphorylation of 170-mer RNA at the 50-end was
conﬁrmed to have proceeded. MALDI–TOF–MS calcd
for the 11-mer RNA fragment pyrophosphorylated at
the 50-end [M+Na]
+, 3755.40; found, 3757.96. MALDI–
TOF–MS calcd for the 25-mer RNA fragment
pyrophosphorylated at the 50-end [M+Na]
+, 8371.06;
found, 8375.65.
Capping and poly(A)-tailing reactions
The capping and poly(A)-tailing reactions were carried
out with the mScript
TM
mRNA Production System
from Epicentre Biotechnologies (Madison, WI, USA).
First, the cap 1 structure, m
7GpppNm, which includes a
50–50-triphosphate linkage, was attached to the 50-end of
the chemically synthesized, 50-pyrophosphorylated
130-mer or 170-mer RNA by incubating the RNA
(300mg) with capping enzyme (480U) and 20-O-
methyltransferase (48U) in 50mM Tris–HCl, pH 8.0, con-
taining 6mM KCl, 1.25mM MgCl2, 1mM GTP, 0.2mM
S-adenosylmethionine and RNase inhibitor (960U) in a
total volume of 1.2ml at 37 C for 2h. The capped RNA
was extracted with phenol/chloroform, concentrated by
ethanol precipitation, and resuspended in RNase-free
water. Then the poly(A) tail was added by incubating
the capped 130-mer RNA with poly(A) polymerase
(150U) in 50mM Tris–HCl, pH 8.0, containing 250mM
NaCl, 10mM MgCl2, 1mM ATP and RNase inhibitor
(300U) in a total volume of 1.8ml at 37 C for 4h. The
capped, poly(A)-tailed RNA was extracted with phenol/
chloroform, concentrated by ethanol precipitation and re-
suspended in RNase-free water. Finally, the artiﬁcial
mRNA was puriﬁed on a MicroSpin G-25 Column
(GE Healthcare, Buckinghamshire, England). Samples
were analyzed by electrophoresis on a 5% denaturing
polyacrylamide gel.
Analysis of MazF digestion products of RNA
MazF is an endoribonuclease that cleaves speciﬁcally at
the 50-end of ACA sequences (17). RNA (10mg) was
incubated with MazF (80U; Takara Bio, Otsu, Japan) in
40mM sodium phosphate, pH 7.5, containing 0.01%
Tween 20 in a total volume of 20mla t3 7  C for 1h. The
digestion products were extracted with phenol/chloro-
form, concentrated by ethanol precipitation, and resus-
pended in RNase-free water. For MALDI–TOF mass
spectrometry, the digestion products were further
puriﬁed on ZipTip C18 reverse-phase microcolumns
(Millipore, Bedford, MA). MALDI–TOF mass spectra
were acquired in positive-ion mode with a matrix
solution consisting of 10mg/ml 3-hydroxypicolinic
acid and 1mg/ml diammonium citrate. The potential
for linear acceleration was 19kV and the potential for
reﬂector acceleration was 20kV. The IS/2 potential
was set at 16.6kV. Ion extraction was delayed by
130ns, and at least 150 shots were accumulated for each
sample.
Expression of GLP-1 peptide in a wheat germ lysate
In vitro expression of GLP-1 peptide with an additional
two N-terminal amino acids, MGHAEGTFTSDVSSYL
EGQAAKEFIAWLVKGRG, was performed with an
RTS 100 Wheat Germ CECF Kit (Roche Diagnostics,
Mannheim, Germany) according to the supplier’s
instructions.
Cell culture and transfection
CHO-K1 cells were grown in Ham’s F-12K medium
(Sigma) supplemented with 2mM L-glutamate, 1.5g/l
sodium bicarbonate, and 10% heat-inactivated fetal
bovine serum at 37 C in a humidiﬁed incubator in an at-
mosphere of 5% CO2 and 95% air. RNA transfections
were performed with Nucleofector Reagent (Amaxa
Biosystems, Cologne, Germany) according to the sup-
plier’s instructions.
Sandwich ELISA
GLP-1 in wheat germ lysate or cell lysate was determined
with a microplate coated with goat anti-mouse IgG
(Pierce, Rockford, IL, USA) used in combination with a
GLP-1 (Active) ELISA Kit (Linco Research, St Charles,
MO, USA) according to the supplier’s instructions. The
goat anti-mouse IgG-coated plate was rinsed with
3 200ml of TBS-T (50mM Tris–HCl, pH 7.5, containing
0.05% Tween 20), after which 0.1mg/ml mouse anti-GLP-
1 antibody HYB147-12 (100ml; Abcam, Cambridge, MA,
USA) in TBS-T was added. The plate was incubated at
37 C for 1h with shaking, each well was washed with
wash buffer (3 300ml), and assay buffer and GLP-1
sample (100ml) were added. The plate was incubated at
4 C for 24h, each well was again washed with wash buffer
(3 300ml), and GLP-1 detection conjugate was added.
The plate was then incubated at room temperature for
2h. Finally, each well was washed with wash buffer
(3 300ml), substrate solution was added, and the ﬂuor-
escence intensity was measured at an excitation
7848 Nucleic Acids Research, 2010,Vol.38, No. 21wavelength of 355nm and an emission wavelength of
460nm with a Wallac ARVO HTS 1420 Multilabel
Counter (Perkin Elmer Life Sciences).
RESULTS AND DISCUSSION
We synthesized artiﬁcial mRNA by (i) solid-phase synthe-
sis of the RNA sequence from CEM amidites, (ii)
monophosphorylation and pyrophosphorylation of the
50-end of the RNA still attached to the solid support,
(iii) cleavage of the pyrophosphorylated RNA from
the solid support followed by deprotection and puriﬁca-
tion, (iv) addition of the 50-cap to the puriﬁed,
pyrophosphorylated RNA with capping enzyme and (v)
polyadenylation of the 30-end of the 50-capped RNA with
poly(A) polymerase (Figure 1). We also synthesized a
170-mer RNA that includes a chemically synthesized
40-mer poly(A) tail as a part of the synthetic sequence.
Including a chemically synthesized poly(A) tail would
reduce the number of enzymatic steps needed, and the
chemically synthesized product would also have the
being a single molecular species, in contrast to the distri-
bution of poly(A) tail lengths obtained with the use of
poly(A) polymerase.
Design of the synthetic sequence
We designed the synthetic sequence of a 130-mer RNA
with a 50-untranslated region (50-UTR), a GLP-1-coding
region, and a 30-UTR (Figure 2). The 20-nt 50-UTR is
followed by a region encoding the 33 amino acids of
GLP-1 from the AUG start codon to the ﬁnal GGA
codon. To increase the efﬁciency of translation, the
50-UTR and the start of the coding region were designed
to include a Kozak consensus sequence, which is
characterized by a purine three bases upstream of the
start codon and a guanine immediately downstream (18).
The synthetic sequence of the 130-mer includes three
MazF cleavage sites, one in the 50-UTR and two near
the start of the coding region (one of the latter was
generated by introducing a silent C!A mutation at
position 41). These cleavage sites facilitated analysis of
the 50-cap by MALDI–TOF mass spectrometry after
MazF digestion. The 8-nt 30-UTR following the stop
codon corresponds to the ﬁrst 8nt of the 30-UTR of the
glucagon gene. Both the 50- and the 30-UTR were short-
ened from the respective untranslated regions of the
glucagon gene to give RNA of a manageable length for
chemical synthesis.
Synthesis of 130-mer RNA and monophosphorylation
of the 50-end
A 130-mer RNA oligomer was synthesized on a 0.6-mmol
scale by the phosphoramidite method modiﬁed for
CEM chemistry (Scheme 1). As in our previous synthesis
of a 110-mer (10), the solid support was CPG with a
pore size of 2000A ˚ derivatized with N
4-benzoyl-20-O-
TBDMS-riboadenosine as the leader nucleoside. (In our
experience, a large-pore resin is necessary to obtain good
yields in the synthesis of very long oligomers.) The
detritylation reagent was trichloroacetic acid in
dichloromethane. For the coupling reaction, amidites
were used as 0.05M solutions in acetonitrile, and the acti-
vator was 5-benzylmercaptotetrazole rather than the
5-ethylthio-1H-tetrazole used in the original method (9)
because it was found to be the most suitable for use with
the CEM method. The capping reagent was a mixture of
Pac2O in THF and NMI and 2,6-lutidine in THF, and the
oxidizing agent was 0.1M I2 in THF/pyridine/water. A
small amount of the 130-mer synthesized as described
earlier was cleaved from the solid support, deprotected
and treated with MazF to generate fragments from the
50-end for analysis by MALDI–TOF mass spectrometry
(Supplementary Figure 3).
The remainder of the 130-mer RNA, while still on the
solid support, was monophosphorylated with phos-
phorylating reagent 1 or 2 (Scheme 1). Phosphorylation
proceeded almost quantitatively with either reagent. After
oxidation and capping, the phosphate-protecting groups
(the cyanoethyl and sulfonylethyl groups) were removed
by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene-
bis(trimethylsilyl)acetamide (DBU–BSA) (12,19). Finally,
130-mer monophosphorylated at the 50-end was converted
to the triethylammonium salt by treatment with
triethylamine-MeOH and used for the pyrophospho-
rylation studies described below.
Tests of reagents for pyrophosphorylation of RNA at
the 50-end
In the cell, the addition of the 50-cap to the nascent mRNA
involves the removal of one phosphate group of the
P
5′ 3′
Pyrophosphate
130mer RNA Cap
poly(A) tail
m7Gpp
P
5′ 3′
P
130mer RNA
Figure 1. Enzymatic conversion of 130-mer to artiﬁcial mRNA.
5„
3„
-GCUACCAGAAGACAGCAGAAAUGGGACAUGCUGAAGGGACAUUUA
CCAGUGAUGUAAGUUCUUAUUUGGAAGGCCAAGCUGCCAAGGAAUUC
AUUGCUUGGCUGGUGAAAGGCCGAGGAUAACUAUAUCA-
(a)
(b)
MGHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
Figure 2. (a) Sequence of artiﬁcial mRNA. Underline, start codon;
italics, stop codon; bold, untranslated regions; blue, Kozak consensus
sequence; red, MazF cleavage sites; enclosed nucleoside, C!A silent
point mutation. (b) Peptide encoded by artiﬁcial mRNA. Green, GLP-1
(residues 7–37 of preproglucagon).
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followed by condensation between GTP and the remain-
ing 50-pyrophosphate terminus catalyzed by the capping
enzyme guanylyl transferase. With a view to using capping
enzyme to prepare capped RNA from RNA
pyrophosphorylated at the 50-end, we investigated the
pyrophosphorylation of 130-mer RNA at the 50-end.
However, existing phosphorylating reagents for
pyrophosphorylation are only poorly reactive (12,13).
Because they are particularly unsuitable for
pyrophosphorylation of the 50-end of a poorly accessible,
very long RNA oligomer attached to the internal pores of
the solid support, we decided to develop more reactive
pyrophosphorylating reagents suitable for use with very
long RNA oligomers. Accordingly, we developed
pyrophosphorylating reagents with a phosphotriester
structure, which is much more reactive than the phospho-
diester structure of existing reagents. We developed the
phosphotriester reagents by reference to a method for
pyrophosphate bond formation reported by Sekine and
coworkers (20). Pyrophosphorylating reagent 3 was
prepared from phosphorylating reagent 1 and ﬁve
equivalents of 1-hydroxy-6-(triﬂuoromethyl)benzotriazole
(CF3-HOBt; Scheme 2). The reaction presumably pro-
ceeded via an O-N phosphoryl rearrangement. Reagent
3 (observed in the
31P NMR spectrum at  1.2ppm) was
prepared in situ for use in pyrophosphorylation studies
without post-processing or puriﬁcation (Supplementary
Figure 1).
We ﬁrst used trimer RNA as a model substrate for
studies of our new pyrophosphorylating reagents
(Scheme 3 and Table 1). Trimer RNA monophosphate
prepared as described above was used as a substrate
for pyrophosphorylation on a CPG solid support
(Supplementary Figure 2). Reagent 3 was prepared by
reaction of 1 and CF3-HOBt at room temperature for
1h. Pyrophosphorylation with 3 gave trimer RNA pyro-
phosphate in 84% yield (Figure 3). Because the amount of
trimer RNA sample obtained by cleavage from the CPG
solid support and removal of the protecting groups was
almost the same for the monophosphate and the pyro-
phosphate, the pyrophosphorylation yield was calculated
by dividing the purity of the trimer RNA pyrophosphate
by that of the trimer RNA monophosphate. Reagent 4,
which was prepared from 2, gave a yield of
pyrophosphorylated product that was a little lower than
that obtained with 3. In addition, the yield obtained with 4
was sensitive to moisture. Pyrophosphorylating reagents
5–7 were prepared with a modiﬁed triﬂuoromethylben-
zotriazole moiety. Pyrophosphorylation with 5, which
lacks a triﬂuoromethyl group on the benzotriazole ring
system, gave trimer RNA pyrophosphate in 61% yield.
Because about 26% of the starting material remained,
the reactivity of 5 was judged to be lower than that of 3.
Pyrophosphorylation with 6, which has a
7-azabenzotriazole moiety, gave a yield similar to that
obtained with 3. However, pyrophosphorylation with 7,
which was expected to be highly reactive, gave only a poor
yield. The 4-nitro-6-(triﬂuoromethyl)benzotriazole moiety
is expected to be a good leaving group, and we suspect
that 7 was so reactive that it had largely decomposed
before reaction with trimer RNA monophosphate could
occur.
We next studied the pyrophosphorylation of very long
RNA oligomers on the 50-end. Pyrophosphorylation of
122-mer RNA monophosphate with 3 gave the RNA
pyrophosphate. However, by-products were observed on
HPLC, even though we used the best reaction conditions
found for the pyrophosphorylation of trimer RNA
monophosphate, conditions under which these
by-products were hardly observed. The by-products may
have been generated by overreaction during
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7850 Nucleic Acids Research, 2010,Vol.38, No. 21pyrophosphorylation. When 5, which is less reactive than
3, was used for the pyrophosphorylation of 122-mer RNA
monophosphate, the pyrophosphate was obtained in rea-
sonable yield without the generation of by-products.
Reagent 5 is therefore the more suitable for the
pyrophosphorylation of very long RNA oligomers.
Pyrophosphorylation of the 122-mer was conﬁrmed by
MALDI–TOF mass spectrometric detection of the
expected 50-end fragment generated by MazF treatment
(Figure 4).
Reagent 3 may be especially suitable for the
pyrophosphorylation of RNA of up to about 20nt, such
as siRNA strands, while 5 is more suitable for the
pyrophosphorylation of RNA longer than about 50nt.
We assume that most of the by-products shown in
Entry1 of Table 1 (for the use of reagent 3) result from
reaction at internucleotide linkages. These by-products
are hardly noticeable for short oligomers but are very no-
ticeable for long oligomers. Reagent 5 should be used
for the 50-pyrophosphorylation of long oligomers
because the side reaction will not occur easily due to the
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phosphotriester pyrophosphorylating reagents that we
have developed can be used for the pyrophosphorylation
not only of nucleic acids but also of small molecules,
peptides and sugars.
Preparation of 50-pyrophosphorylated 130-mer
and 170-mer RNA
Pyrophosphorylation of 130-mer and 170-mer RNA
monophosphates was carried out with reagents 3, 4 and
5. After pyrophosphorylation, the protecting groups of
the phosphate group at the 50-end (the cyanoethyl and
sulfonylethyl groups) were removed by treatment with
DBU–BSA. Cleavage of the oligomers from the CPG
solid support and removal of the base-protecting groups
was carried out by treatment with a mixture of 28%
aqueous ammonia and EtOH (3:1, v/v) at 35 C for 15h.
The CEM protecting group was removed by treatment
with 0.67M TBAF in DMSO, with 0.67% nitromethane
as an acrylonitrile scavenger, at room temperature for 5h
(Supplementary Figure 4) (21). Puriﬁcation was carried
out by semipreparative HPLC on a DNAPac PA 100
column and pure fractions were desalted by dialysis. The
total yields of 130-mer and 170-mer
50-pyrophosphorylated oligomers, including both the syn-
thetic and the pyrophosphorylation steps, were 8.0 and
4.8%, respectively, corresponding to respective average
coupling yields of 98.1 and 98.2% (Figure 5).
Enzymatic steps in the production of artiﬁcial mRNA
To attach the cap 1 structure to the 50-end of the
50-pyrophosphorylated 130-mer or 170-mer RNA
oligomer, we used a combination of a capping system
Table 1. Product distribution observed after 50-pyrophosphorylation of trimer RNA
Entry Reagent Reaction
time (h)
HPLC peak area (%) Yield (%)
50-Pyrophosphate
(14.3min)
a
50-Monophosphate
(11.7min)
By-products
1
(9.1min)
2
(12.8min)
3
(19.2min)
Others
1 3 1 76.0 3.6 1.9 4.0 2.6 11.9 84
2 4 2 65.0 7.5 4.9 7.9 4.7 10.0 72
3 5 1 55.5 26.4 5.0 0.8 2.0 10.3 61
4 6 1 71.3 5.0 7.0 1.2 5.4 10.1 78
5 7 0.25 2.7 6.9 35.1 2.6 26.9 25.8 3
aThe numbers in parentheses are the HPLC retention times.
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The numbers 1–3 correspond to the by-products 1–3 shown in Table 1.
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the formation of the cap 0 structure from GTP
and 50-pyrophosphorylated RNA, while 20-O-
methyltransferase completes the formation of the cap 1
structure by adding a methyl group at the 20-O-position
of the second nucleotide from the 50-end of the RNA
molecule (the ﬁrst nucleotide before the addition of cap
0). Cap 1 rather than cap 0 was used because it confers a
higher translation efﬁciency (22).
Whereas the 170-mer RNA has a chemically synthesized
40-mer poly(A) tail, the 130-mer RNA does not have a
poly(A) tail. To add a poly(A) tail to the 130-mer, we used
poly(A) polymerase, which catalyzes the template-
independent addition of poly(A) to the 30-end of the
RNA with ATP as a substrate. To conﬁrm that cap 1
had been correctly added, both RNA oligomers were
digested with MazF and the digestion products were
analyzed by MALDI–TOF mass spectrometry. MazF di-
gestion of uncapped 130-mer produced, as expected, an
11-nt fragment of molecular weight 3734Da that
included the 50-end (Figure 6A, upper panel), while
capped 130-mer produced the expected 12-nt fragment
of molecular weight 4107Da (Figure 6A, lower panel).
The difference in molecular weight, 373Da, corresponds
exactly to the molecular weight of the cap 1 structure
(Table 2). Similar results were obtained for the 170-mer
RNA (Figure 6B). These experiments demonstrate that
cap 1 was correctly attached to both the 130-mer and
the 170-mer RNA. A MazF digestion product of molecu-
lar weight 3654Da corresponds to the 50-end fragment
derived from 50-monophosphorylated RNA, which
cannot act as a substrate in the capping system.
Accordingly, this fragment showed no change after treat-
ment of 50-monophosphorylated RNA with capping
enzyme and 20-O-methyltransferase (Figure 6A).
To conﬁrm that the poly(A) tail had been added,
130-mer RNA that had been treated with poly(A) poly-
merase in the presence of ATP was analyzed by electro-
phoresis on a denaturing 5% polyacrylamide gel
(Figure 7A). The 130-mer was converted to a
higher-molecular-weight form consistent with the
addition of a poly(A) tail of  70nt. However, unchanged
130-mer remained that had not been polyadenylated.
Polyadenylation may have been incomplete because
some of the 130-mer retained the TBDMS group used to
protect the 30-end nucleoside. The deprotection conditions
were speciﬁcally designed for the removal of CEM, and
TBDMS is known to be incompletely removed by TBAF
(23–25). A poly(A) tail presumably cannot be attached to
RNA that retains the TBDMS group at the 30-end because
such RNA may be a poor substrate for poly(A) polymer-
ase. When CEM was used as the 30-end protecting group
instead of TBDMS, the 130-mer was fully polyadenylated
(Figure 7D), consistent with the fact that the CEM group
is easily removed by TBAF treatment. We cannot quote
the yield of the ﬁnal puriﬁed artiﬁcial mRNA because of
the distribution of poly(A) tail lengths.
Biological activity of artiﬁcial mRNA
Chemically synthesized 130-mer and 170-mer RNA
encoding GLP-1 peptide was enzymatically treated as
described earlier to produce a GLP-1 artiﬁcial mRNA.
To assess the biological activity of this artiﬁcial mRNA,
we performed GLP-1-expression experiments in a cell-free
protein synthesis system and in whole cells and used
sandwich ELISA to determine GLP-1 produced.
A eukaryotic cell-free protein synthesis system based on
wheat germ lysate was used to express GLP-1 peptide. As
a negative control, an RNA that would not be expected to
support translation was synthesized. This negative control
was a 127-mer that was identical to the 130-mer except
that it lacked the second codon, GGA, so that it had a
disrupted Kozak sequence. We showed that mRNA
derived from the 127-mer had the cap 1 structure and a
poly(A) tail consisting of  60nt (Figures 6C and 7C). As
expected, this mRNA did not support the expression of
GLP-1, whereas mRNA derived from both the 130-mer
and the 170-mer supported GLP-1 expression in a
dose-dependent manner (Figure 8). These results demon-
strate that artiﬁcial mRNA derived from chemically
synthesized RNA functioned in vitro. In addition, the
length of the 50-UTR and of the poly(A) tail affected the
translation efﬁciency, as reported earlier (26,27). Thus,
Time (min)  Time (min) 
B A
Figure 5. Anion-exchange HPLC of puriﬁed 50-pyrophosphorylated RNA 130-mer (A) and 170-mer (B).
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supported only a low level of GLP-1 expression compared
with mRNA derived from the 130-mer, which had a 20-nt
50-UTR (data not shown). And mRNA derived from the
130-mer, which had a longer average length of poly(A) tail
than the 170-mer mRNA (Figure 7A and B), supported
the expression of GLP-1 slightly better than did the
170-mer (Figure 8).
To test the ability of the artiﬁcial mRNA to support
GLP-1 expression in whole cells, we transfected CHO
cells with artiﬁcial mRNA by electroporation. Twelve
hours after transfection, cells were harvested and GLP-1
was determined by sandwich ELISA. Control RNA that
had not been subjected to enzymatic treatment to generate
cap 1 or a poly(A) tail did not support GLP-1 expression,
whereas mRNA derived from both the 130-mer and the
170-mer RNA supported weak GLP-1 expression
(Figure 9). The weak GLP-1 expression and the lack of
dose dependence may be explained by factors such as the
stability of the mRNA in the cell culture medium, the
transfection efﬁciency and the length of both the 50-UTR
and the poly(A) tail. Cationic liposomes were also tried as
a method to deliver the mRNA to the cells, but the results
were no better than those obtained with electroporation.
Further work is required to establish the utility of artiﬁcial
mRNA in whole cells.
In the present study, we have shown that mRNA
derived from a chemically synthesized 170-mer RNA
encoding a 33-amino-acid peptide supported the expres-
sion of the peptide in a cell-free system and in whole cells.
Biologically active peptides are usually translated as long
precursors that undergo processing in the endoplasmic re-
ticulum (ER) (28,29). There are several reports of peptides
being translated from mRNA with an open reading frame
(ORF) of fewer than 100 amino acids. A 36-amino-acid
peptide was shown to be translated in Saccharomyces
cerevisiae from mRNA with a short ORF (30), and a
similar result was obtained for an 11-amino-acid peptide
in Drosophila (31). These short peptides translated from
short ORFs are thought to be localized in the cytosol
during their biosynthesis and not moved to the ER
because they do not need to undergo processing there.
The functions of these short peptides are presumably
distinct from those of peptides that mature in the ER.
Non-coding RNA with a relatively long poly(A) tail at
the 30-end, known as mRNA-like non-coding RNA, also
exists (32,33). It includes bifunctional RNA (34)
transcribed from genes such as oskar in Drosophila,
which acts as a non-coding RNA during early oogenesis
and as an mRNA during the embryonic stage (35). The
technology for synthesizing mRNA reported in the
present paper can provide access to such bifunctional
and multifunctional RNAs, allowing expansion of basic
and applied research in this area.
1
2
6
A
B
C
4
3
5
m/z
m/z
m/z 
Figure 6. MALDI–TOF mass spectrometry of MazF digestion
products of RNA oligomers. (A) 130-mer, (B) 170-mer and (C)
127-mer. The upper panels show the mass spectra of the MazF diges-
tion products of uncapped RNA and the lower panels those of capped
RNA.
Table 2. Masses of 50-end fragments produced by MazF digestion
RNA
molecule
Peak
no.
a
Pyrophosphate Peak
no.
a
Cap 1 Mass
difference
(b a) Calculated
mass
Observed
mass (a)
Calculated
mass
Observed
mass (b)
130-mer 1 3734.6 2 4107.4 372.8
170-mer 3 3734.2 3756.7 4 4107.4 4130.2 373.5
127-mer 5 3734.7 6 4107.7 373
aPeak numbers correspond to the numbered fragments shown in
Figure 6.
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We have developed novel, highly active pyrophospho-
rylating reagents based on a phosphotriester structure
that are suitable for the pyrophosphorylation of short
and long RNA oligomers. In particular, our
phosphotriester pyrophosphorylating reagents solve the
problem of the pyrophosphorylation of long RNA oligo-
mers on a solid support. We have designed mRNA se-
quences up to 170nt long and used the CEM method to
chemically synthesize each of them in a single synthesizer
run. This extends the length of RNA oligomer shown to
be capable of being handled by the CEM method from the
previously reported maximum of 110. Synthetic 130-mer
and 170-mer RNA oligomers were monophosphorylated,
pyrophosphorylated with our new reagents, and
enzymatically capped and poly(A)-tailed. Electrophoretic
and mass-spectrometric analysis of the products showed
that both synthetic oligomers had been correctly con-
verted to mRNA that supported protein synthesis in a
cell-free system and in whole cells. As far as we know,
this is the ﬁrst report of the preparation of a mature
mRNA from a chemically synthesized sequence. The tech-
nology for preparing mRNA described in this paper is
expected to be useful in basic and applied research on
new functional RNA as well as in the development of
RNA vaccines and mRNA medicines.
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Figure 7. Polyacrylamide gel electrophoresis of the poly(A)-tailing reaction. RNA oligomers were analyzed on a 5% denaturing polyacrylamide gel
stained with ethidium bromide. 130-mer, 170-mer and 127-mer: chemically synthesized RNA. 130-mer mRNA, 170-mer mRNA and 127-mer mRNA:
enzymatically capped and poly(A)-tailed RNA (except for the 170-mer, which included a chemically synthesized poly(A) tail). 130-mer mRNA
(CEM): enzymatically capped and poly(A)-tailed RNA in which CEM instead of TBDMS was used as the 30-end protecting group.
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Figure 8. GLP-1 expression in vitro. Artiﬁcial mRNA was added to a
wheat germ cell-free protein synthesis system and GLP-1 expression
was determined by sandwich ELISA. Each value is the average of
three independent experiments, and the error bars indicate the
standard deviation.
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